Literature DB >> 3859929

High-dose cytosine arabinoside in the treatment of resistant acute leukemia.

F Takaku, A Urabe, H Mizoguchi, O Yamada, Y Wakabayashi, Y Miura, S Sakamoto, M Yoshida, S Miwa, S Asano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3859929

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 2.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

Review 3.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

4.  Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.

Authors:  M Freund; S Giller; F Hinrichs; A Baars; J Meran; A Körfer; H Link; H Poliwoda
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.